West Pharma (WST) Tops Q4 EPS by 20c, provides guidance

West Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.20 better than the analyst estimate of $1.84. Revenue for the quarter came in at $805 million versus the consensus estimate of $796.25 million.

GUIDANCE:

West Pharma sees FY2026 EPS of $7.85-$8.20, versus the consensus of $7.76.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance
• Bp sells stakes in Brazil and Gulf of America assets to Shell